FDA rejects Xarelto for preventing stent thrombosis in ACS

06/30/2013 | Forbes · Bloomberg · Healio

The FDA rejected a request from Johnson & Johnson and Bayer AG to expand the use of their blood thinner rivaroxaban, or Xarelto, to prevent stent thrombosis in patients with acute coronary syndrome. The FDA has asked J&J's Jannsen Pharmaceuticals for more information about the drug's use in ACS patients. The agency previously declined a supplemental new drug application for general use of the drug to treat ACS.

View Full Article in:

Forbes · Bloomberg · Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI